From the Department of Dermatology, Feinberg School of Medicine at Northwestern University, Chicago, IL.
Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC.
Dermatitis. 2022;33(6S):S17-S23. doi: 10.1097/DER.0000000000000799. Epub 2021 Oct 18.
The management required for atopic dermatitis (AD) may worsen patient burden, thereby resulting in iatrogenic burden, that is, morbidity caused by medical treatment. We sought to describe the iatrogenic burden of AD and conducted a narrative review of key areas that clinicians can address to minimize it. Clinicians should think strategically about itch trigger avoidance, encourage slow incorporation of lifestyle changes, and emphasize step-up therapy when avoidance becomes too burdensome. Out-of-pocket treatment costs should be incorporated into shared decision making to balance affordability, preference, efficacy, and safety. Polypharmacy should be minimized by eliminating ineffective, nonevidence-based, and redundant therapies while appropriately stepping up to advanced therapy. Clinicians should take adequate time to communicate, the impact of AD on quality of life, and incorporate evidence-based guidelines. The multidimensional nature of AD requires a dynamic approach. Future guidelines should incorporate step-up, step-down, and maintenance approaches to reduce treatment burden and improve quality of life.
特应性皮炎(AD)的管理可能会加重患者负担,从而导致医源性负担,即治疗引起的发病率。我们旨在描述 AD 的医源性负担,并对临床医生可以解决的关键领域进行叙述性综述,以最大程度地减少医源性负担。临床医生应战略性地考虑避免瘙痒触发因素,鼓励缓慢进行生活方式改变,并在避免变得过于繁琐时强调逐步升级治疗。应将自付治疗费用纳入共同决策,以平衡可负担性、偏好、疗效和安全性。通过消除无效、无证据支持和冗余的治疗方法,同时适当升级到高级治疗,尽量减少多药治疗。临床医生应花足够的时间进行沟通,告知 AD 对生活质量的影响,并纳入基于证据的指南。AD 的多维性质需要采取动态方法。未来的指南应纳入逐步升级、逐步降级和维持治疗方法,以减轻治疗负担并提高生活质量。